Zacks Research Analysts Lower Earnings Estimates for Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Zacks Research dropped their Q4 2024 earnings per share estimates for shares of Gilead Sciences in a research report issued to clients and investors on Monday, October 7th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $1.45 for the quarter, down from their previous estimate of $1.47. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.78 per share. Zacks Research also issued estimates for Gilead Sciences’ Q2 2025 earnings at $1.70 EPS and FY2025 earnings at $7.12 EPS.

GILD has been the subject of a number of other reports. Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a report on Monday, September 16th. Piper Sandler reiterated an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a report on Wednesday, September 11th. Truist Financial lifted their target price on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday. Eleven research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $84.83.

Gilead Sciences Stock Up 1.1 %

Shares of Gilead Sciences stock opened at $86.14 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $87.86. The business has a fifty day simple moving average of $79.34 and a 200 day simple moving average of $72.07. The stock has a market cap of $107.32 billion, a PE ratio of 239.28, a price-to-earnings-growth ratio of 2.91 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors have recently bought and sold shares of GILD. CarsonAllaria Wealth Management Ltd. increased its position in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 238 shares during the last quarter. Palisade Asset Management LLC acquired a new position in Gilead Sciences during the first quarter worth approximately $29,000. Cedar Wealth Management LLC increased its position in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the second quarter worth approximately $33,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is owned by insiders.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date was Friday, September 13th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.